Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Aytu BioScience announces business strategy update and Q2 financial results

Aytu BioScience, Inc., a specialty healthcare company focused on developing treatments for urological and related conditions, provided today an overview of its business and growth strategy, as well as its financial results for the quarter ended December 31, 2015.

17 Feb 2016

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).

10 Dec 2015

Novel antidepressant appears to be safe, effective against depression in clinical trial

A small clinical trial of a novel antidepressant that stimulates neurogenesis - the production of new brain cells - shows that the compound appears to be safe and may be effective against depression.

9 Dec 2015

UVA opens clinical trial to examine non-surgical treatment for lower urinary tract symptoms

University of Virginia Health System researchers have opened a national clinical trial examining a non-surgical treatment for lower urinary tract symptoms caused by an enlarged prostate.

30 Nov 2015

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the nine months ended September 30, 2015 and updates on its drug development programs.

27 Nov 2015

Multicenter trial compares popular treatments for menopause-related vaginal symptoms

Hot flashes. Night sweats. These are the most common - or at least the most commonly talked about - symptoms of menopause. But one reality of The Change for many women is less discussed yet no less important: problems with vaginal health and sexual function.

6 Nov 2015

Men and women see lasting improvements in sex lives after bariatric surgery

Both men and women see lasting improvements in their sex lives after bariatric surgery, according to a new study, funded by the National Institutes of Health and presented here at ObesityWeek 2015, the largest international event focused on the basic science, clinical application and prevention and treatment of obesity.

5 Nov 2015

Sexual dysfunction prevalent among recent combat veterans

In a recent study of 247 US veterans returning from conflicts in Iraq and Afghanistan, almost 18% screened positive for sexual functioning difficulties. Self-reported sexual dysfunction was most strongly linked with depression, post-traumatic stress disorder, and female sex.

4 Nov 2015

Expert proposes new solution to current gridlock over regulation of dietary supplements

A former principal deputy commissioner of the U.S. Food and Drug Administration is proposing a solution to the current gridlock over the regulation of dietary supplements: Focus less on whether these vitamins, minerals and herbal extracts actually do what they claim and instead take important steps to improve their safety.

3 Nov 2015

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Transition Therapeutics Inc. announced today that Transition Therapeutics Ireland Limited has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women's Hospital.

30 Oct 2015

Genetic discovery sheds light on how prostate cancer develops and spreads

A new and important genetic discovery, which sheds light on how prostate cancers develop and spread, has been made by an international research team led by scientists at The University of Nottingham.

27 Oct 2015

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the most common form of liver cancer.

12 Oct 2015

Hormonal therapy may protect women's ovaries, increase chances of pregnancy after breast cancer treatment

Young women undergoing chemotherapy for breast cancer may be more likely to remain fertile if they also receive hormonal treatment, according to new research presented to the 2015 European Cancer Congress on Monday and published simultaneously in Annals of Oncology.

28 Sep 2015

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2015.

21 Sep 2015

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today reported positive data from the completed Phase 1 multiple ascending dose, placebo controlled clinical trial of BNC210, an orally administered negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor (alpha-7 receptor) being developed for the treatment of anxiety and depression.

16 Sep 2015

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs.

28 Aug 2015

Valeant enters into definitive agreement to acquire Sprout Pharmaceuticals

Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.

20 Aug 2015

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual desire disorder (HSDD).

20 Aug 2015

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin's lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD).

19 Aug 2015

Even the Score issues statement on FDA approval of flibanserin for treatment of women with HSDD

Even the Score issued the following statement following today's historic approval by the Food and Drug Administration of flibanserin (Addyi), the first-ever medical treatment option for women's most common sexual dysfunction, known as Hypoactive Sexual Desire Disorder (HSDD).

18 Aug 2015

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Aytu BioScience announces business strategy update and Q2 financial results

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Novel antidepressant appears to be safe, effective against depression in clinical trial

UVA opens clinical trial to examine non-surgical treatment for lower urinary tract symptoms

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Multicenter trial compares popular treatments for menopause-related vaginal symptoms

Men and women see lasting improvements in sex lives after bariatric surgery

Sexual dysfunction prevalent among recent combat veterans

Expert proposes new solution to current gridlock over regulation of dietary supplements

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Genetic discovery sheds light on how prostate cancer develops and spreads

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Hormonal therapy may protect women's ovaries, increase chances of pregnancy after breast cancer treatment

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Valeant enters into definitive agreement to acquire Sprout Pharmaceuticals

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Even the Score issues statement on FDA approval of flibanserin for treatment of women with HSDD

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in